Return to Headlines
Rocky Mountain Ginseng, Inc. Announces Resignation of Robert L.
Bell <RMGG.OB>
Rocky Mountain Ginseng, Inc. Announces Resignation of Robert L. Bell VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 27, 2000-- Rocky Mountain Ginseng, Inc. (OTCBB:RMGG) announces that, in order to pursue other personal interests, Robert Bell has submitted his resignation as President and Director effective, January 12, 2000. In his letter Bell stated, "My reasons for resigning are purely personal and in no way relate to the Directors or Rocky Mountain. Working with the Board in bringing Rocky Mountain Ginseng Inc. to its present position will always be warmly remembered." ABOUT ROCKY MOUNTAIN GINSENG, INC. Rocky Mountain Ginseng, Inc.'s head office is located in British Columbia, Canada. The company exports American ginseng to China as well as manufactures and processes America ginseng products in China. Rocky Mountain Ginseng, Inc. holds exclusive world processing and distribution rights to several innovative value added ginseng products developed in North America. Rocky Mountain Ginseng, Inc. purchased Fuzhou Fujian Drug Company located in China in February 1999. This acquisition included all necessary drug and hygiene licenses allowing the company to import, export, manufacture and distribute ginseng products in all provinces of China. The company has completed the construction of its new office and manufacturing facility in the city of Fuzhou and is currently producing traditional ginseng products for the Chinese Market. The Chinese factory employs 27 people in processing, sales, accounting and management. Rocky Mountain (Fuzhou) Drug Co. Ltd. is the first wholly owned American Company in the Fujian province. This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Expression of future goals and similar expressions reflecting something other than historical fact involve risks and uncertainties. The actual results the company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. --30--AMP/se* CONTACT: Rocky Mountain (Fuzhou) Drug Co. Ltd. Brian A. Hodge, (86) 591-379-7969 rockymtpublic.fz.fj.cn www.RMGGInvestor.com or PMR & Associates, LLC Patrick Rost, 760/942-0015 (Investor Relations) pmrandcoaol.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com (c) 1998 Business Wire
|
